May 25, 2023 03:07 PM EDT

Janssen reports decline in 2022 net prices as out-of-pocket costs grow

Nicole DeFeudis

Editor

While net prices for Janssen’s commercial drugs have declined for the sixth consecutive year, out-of-pocket costs have continued to rise for some patients, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Janssen reports decline in 2022 net prices as out-of-pocket costs grow

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Janssen re­ports de­cline in 2022 net prices as out-of-pock­et costs grow

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Janssen reports decline in 2022 net prices as out-of-pocket costs grow